FZ008-145

FZ008-145 is a highly selective, second-generation small molecule inhibitor of the voltage-gated sodium channel Nav1.8 (also known as SCN10A). It is being developed as a non-addictive analgesic for the treatment of pain, with an emphasis on both acute and chronic pain conditions. The drug was designed to offer potent pain relief while minimizing off-target effects and addiction potential by targeting Nav1.8 with high selectivity. Developed using AI-driven drug discovery platforms, FZ008-145 represents an innovative approach in central nervous system (CNS) therapeutics where current options are limited in efficacy and safety. The compound has received IND approval from the China NMPA and is currently undergoing Phase 1 clinical trials in healthy volunteers[1][2][3][4][5][6].